

NIH hepatitis C funding spent on HIV research projects

Funding Institute	Project Title	PI Name	Organization Name	State / Country	Amount
NIAID	Noncarbohydrate Approaches to AntiAIDS Nucleosides	LIOTTA, DENNIS	EMORY UNIVERSITY	GA	\$324,651
NIDA	Nutritional Status In HIV Hispanic Drug Abusers	FORRESTER, JANET	TUFTS UNIVERSITY BOSTON	MA	\$660,216
NIDA	The Logics for HIV Risk Among Homeless Heroin Injectors	BOURGOIS, PHILIPPE	UNIVERSITY OF PENNSYLVANIA	PA	\$360,811
FIC	Risk Factors for HIV-1 infection Among Young Thai Men	RANGSIN, RAM	PHRAMONGKUTKLAO COLLEGE OF MEDICINE	THAIL	\$51,202
NIMH	Neurobehavioral Effects of HIV & Host Genetics in China	HEATON, ROBERT	UNIVERSITY OF CALIFORNIA SAN DIEGO	CA	\$645,840
NIDA	Reducing HIV Risk Among Methamphetamine IDUs Through Peer Education	RUMPTZ, MAUREEN	MULTNOMAH COUNTY HEALTH DEPARTMENT	OR	\$150,780
NIDA	Couples-Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan	EL-BASSEL, NABILA	COLUMBIA UNIV NEW YORK MORNINGSIDE	NY	\$676,058
NIDA	Drug Interactions in Substance Abusers with HIV Infection	FRIEDLAND, GERALD	YALE UNIVERSITY	CT	\$372,375
Total \$\$ within the \$93 million HCV budget spent on HIV					\$3,241,933

NIH hepatitis C funding spent on HIV/HCV co-infection research projects

NIDA	Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid Users	TAYLOR, LYNN	MIRIAM HOSPITAL	RI	\$179,212
NIMH	Role of evolving white matter damage in neurocognitive effects of HIV and HCV	JERNIGAN, TERRY	UNIVERSITY OF CALIFORNIA SAN DIEGO	CA	\$347,625
NIMH	Adherence to HCV Treatment in HCV and HCV/HIV Patients	WEISS, JEFFREY	MOUNT SINAI SCHOOL OF MEDICINE OF NYU	NY	\$148,791
NIDDK	Liver Disease Associated with HCV/HIV Coinfection Due to TRAIL	VLAHAKIS, STACEY	MAYO CLINIC COLL OF MEDICINE, ROCHESTER	MN	\$181,300
NIAID	Immunity of neoantigen response in HCV, HIV, and HCV-HIV	ANTHONY, DONALD	CASE WESTERN RESERVE UNIVERSITY	OH	\$189,456
NIMH	Neurobehavioral Effects of HIV & Host Genetics in China	HEATON, ROBERT	UNIVERSITY OF CALIFORNIA SAN DIEGO	CA	\$645,840
NIDDK	Kidney Disease in HIV-Hepatitis C Virus Co-Infection	WYATT, CHRISTINA	MOUNT SINAI SCHOOL OF MEDICINE OF NYU	NY	\$129,225
NIMH	Enhancing HCV Treatment Decisions in HIV Co-Infected Patients and Their Providers	WAGNER, GLENN	RAND CORPORATION	CA	\$238,108
NIDA	Opioids, HIV/HCV and Host Cell Innate Immunity	HO, WENZHE	CHILDREN'S HOSPITAL OF PHILADELPHIA	PA	\$402,864
NIDA	Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients	PILLAI, SATISH	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA	\$180,360
NIAID	HCV and HIV Progression in Women on HAART	KOVACS, ANDREA	UNIVERSITY OF SOUTHERN CALIFORNIA	CA	\$533,057
NIAID	Thrombocytopenia & HIV/HCV: Risk Factors & Treatment	MARKS, KRISTEN	WEILL MEDICAL COLLEGE OF CORNELL UNIV	NY	\$131,490
NIAID	HIV-Hepatitis C Virus Interactions and Pathogenesis	CHUNG, RAYMOND	MASSACHUSETTS GENERAL HOSPITAL	MA	\$375,067
NIAID	Improving HIV and HCV outcomes in U.S. AIDS Drug Assistance Programs	LINAS, BENJAMIN	MASSACHUSETTS GENERAL HOSPITAL	MA	\$135,815
NIDA	Staying Safe: Long-Term Injection Drug Users Who Have Avoided HIV & Hepatitis C	FRIEDMAN, SAMUEL	NATIONAL DEVELOPMENT & RES INSTITUTES	NY	\$599,233
NIDA	Natural History of Hepatitis C Infection in HIV Disease	COTTON, DEBORAH	BOSTON UNIVERSITY MEDICAL CAMPUS	MA	\$866,282
NIAID	Risk factors and prediction of liver disease in HIV/HCV	LO RE, VINCENT	UNIVERSITY OF PENNSYLVANIA	PA	\$133,029
NIDA	Substance Abuse, HIV and HCV Treatments to Improve Health Outcomes in Drug Users	BRUCE, ROBERT	YALE UNIVERSITY	CT	\$174,077
NIAID	Gender Effects of HIV and HCV on lipodystrophy, glucose disorders, and steatosis	TIEN, PHYLLIS	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA	\$121,770
NIDA	Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana	STRATHDEE, STEFFANIE	UNIVERSITY OF CALIFORNIA SAN DIEGO	CA	\$706,524
NIAID	HCV Replication and Immune Response in HIV Coinfection	GRETCH, DAVID	UNIVERSITY OF WASHINGTON	WA	\$568,445
NIDA	HIV HCV Coinfection Antiviral Therapy and Fibrosis	THOMAS, DAVID	JOHNS HOPKINS UNIVERSITY	MD	\$499,538
NIDA	INNATE IMMUNE DEFENSE AGAINST HCV and HIV: THE CHIMERIC MOUSE MODEL	GALE, MICHAEL	UNIVERSITY OF WASHINGTON	WA	\$378,489
NIDA	HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants	BAUM, MARIANNA	FLORIDA INTERNATIONAL UNIVERSITY	FL	\$521,643
NIGMS	Structure, dynamics, and function of the viroporins Vpu from HIV and p7 from HCV	OPELLA, STANLEY	UNIVERSITY OF CALIFORNIA SAN DIEGO	CA	\$303,961
NIDA	Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana	STRATHDEE, STEFFANIE	UNIVERSITY OF CALIFORNIA SAN DIEGO	CA	\$54,773

NIMH	Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy	HINKIN, CHARLES	BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE	CA	\$605,589
NIDA	HCV Disease Management in HIV- HCV Coinfected IDUs	SULKOWSKI, MARK	JOHNS HOPKINS UNIVERSITY	MD	\$402,468
NIGMS	Inhibition of HCV as an Opportunistic HIV Co-infection	HOSMANE, RAMACHANDRA	UNIVERSITY OF MARYLAND BALT CO CAMPUS	MD	\$342,938
NIAAA	Effect of alcohol and opioids on DC function in HCV and HIV infection	YONKERS, NICOLE	CASE WESTERN RESERVE UNIVERSITY	OH	\$40,972
NIAAA	Interaction of Alcohol and HAART in HIV/AIDS and HIV/AIDS and HCV Coinfection	MCCANCE-KATZ, ELINORE	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA	\$437,882
NIAAA	A Novel Humanized Mouse Model for Studying HIV/HCV Co-Infection and Liver Disease	SU, LISHAN	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL	NC	\$173,738
NIDA	Sino-US Symposium in Drug Abuse, HIV and HCV Comorbidity	HE, JOHNNY	INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS	IN	\$25,000
NIDA	Opioids, HIV/HCV and Host Cell Innate Immunity	HO, WENZHE	CHILDREN'S HOSPITAL OF PHILADELPHIA	PA	\$7,020
NIDA	HIV HCV Coinfection Antiviral Therapy and Fibrosis	THOMAS, DAVID	JOHNS HOPKINS UNIVERSITY	MD	\$100,529
NIDA	HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants	BAUM, MARIANNA	FLORIDA INTERNATIONAL UNIVERSITY	FL	\$66,484
NIAAA	Sino-US Symposium in Drug Abuse, HIV and HCV Comorbidity	HE, JOHNNY	INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS	IN	\$15,000
NCRR	LONG-TERM ANTIVIRAL MANAGEMENT OF HCV AND HIV-1 COINFECTED SUBJECTS (SLAM-C)	WOHL, DAVID	UNIVERSITY OF NORTH CAROLINA CHAPEL HILL	NC	\$7,283
NCRR	HCV-HIV COINFECTION: IMPACT OF IMMUNE DYSFUNCTION	STERLING, RICHARD	VIRGINIA COMMONWEALTH UNIVERSITY	VA	\$354,208
NCRR	SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV	JOHNSON, RAY	INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS	IN	\$6,133
NCRR	SUPPRESSIVE LONG-TERM ANTIVIRAL MANAGEMENT OF HEPATITIS C VIRUS (HCV) AND HIV	MOE, ARDIS	UNIVERSITY OF CALIFORNIA LOS ANGELES	CA	\$31,623
NCRR	HIV ON HEPATITIS C	BONA, ROBERT	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT	CT	\$1,842
NIDCR	HIV ON HEPATITIS C	BONA, ROBERT	UNIVERSITY OF CONNECTICUT SCH OF MED/DNT	CT	\$29
NCRR	SUPPRESSIVE LONG-TERM ANTIVIRAL MGMT OF HCV & HIV-1 COINFECTED SUBJECTS (SLAM-C)	CAMPBELL, THOMAS	UNIVERSITY OF COLORADO DENVER	CO	\$14,142
NCRR	HCV INFECTION AND HCV/HIV CO-INFECTION IN LIVER TISSUE	KATZE, MICHAEL	BATTELLE PACIFIC NORTHWEST LABORATORIES	WA	\$52,949
NIAID	THERAPEUTIC STRATEGIES FOR THE MANAGEMENT OF HCV/HIV CO-INFECTION	FAUCI, ANTHONY	DIRECTOR, NIAID AT THE NIH OVERSEEING INFECTIOUS DISEASE FUNDING OF HCV AND HIV		\$183,595

Total funding within the \$93 million HCV budget that is being spent on HIV/HCV co-infection \$11,615,398

Total funding within the \$93 million HCV budget that is being spent on HIV alone and HIV/HCV co-infection \$14,857,331

Clearly, these HIV related research projects should be funded by the \$2.9 billion HIV budget, not the small HCV budget.

NIH hepatitis C funding spent on Substance Abuse projects

NIDA	Electronic Information System to Enhance Practice at an Opioid Treatment Program	BROWN, LAWRENCE	ADDICTION RESEARCH AND TREATMENT CORP	NY	\$179,626
NIDA	Mediation Effect of Network Function on Transition to Injection Drug Use	LIU, HONGJIE	VIRGINIA COMMONWEALTH UNIVERSITY	VA	\$215,840
NIDA	Treatment Study Using Depot Naltrexone(1/6)Philadelphia Coord/Data Mgmt Site	O'BRIEN, CHARLES	UNIVERSITY OF PENNSYLVANIA	PA	\$591,774
NIDA	Treatment Studies Using Depot Naltrexone (4/6) Columbia Protocol Treatment Site	NUNES, EDWARD	NEW YORK STATE PSYCHIATRIC INSTITUTE	NY	\$380,536
NIDA	Treatment Study Using Depot Naltrexone(2/6)Rhode Island Protocol Treatment Site	FRIEDMANN, PETER	RHODE ISLAND HOSPITAL (PROVIDENCE, RI)	RI	\$355,583
NIDA	Treatment Study Using Depot Naltrexone(5/6)Baltimore Protocol Treatment Site	KINLOCK, TIMOTHY	FRIENDS RESEARCH INSTITUTE, INC.	MD	\$309,076
NIDA	Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site	LEE, JOSHUA	NEW YORK UNIVERSITY SCHOOL OF MEDICINE	NY	\$378,064

Total funding within the \$93 million HCV budget that is being spent on Substance Abuse projects \$2,410,499
Substance Abuse projects offer no benefit towards solving the cellular complexities of the HCV virus

Other NIH hepatitis C funding spent on projects not categorized as HCV specific

NCI	Discovering Disease Susceptibility Genes in African Americans	SMITH, MICHAEL	NIH		\$123,133
NCI	Multidisciplinary Studies of Lymphoma	HARTGE, PATRICIA	NIH		\$1,222,206

NCI	Tumor models for the study of inflammation and oncogenesis	WILTROUT, ROBERT	NIH		\$270,744
NIAAA	Translational Core	WRIGHT, TERESA	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA	\$26,423
NIAID	Translational Core	WRIGHT, TERESA	UNIVERSITY OF CALIFORNIA SAN FRANCISCO	CA	\$191,548
NCI	Epidemiology of Oncogenic Viruses	O'BRIEN, THOMAS	NIH		\$1,060,598
NIGMS	STRUCTURE AND FUNCTION OF HUMAN TRANSLATION COMPLEXES	DOUDNA, JENNIFER	UNIVERSITY OF CALIFORNIA BERKELEY	CA	\$519,180
NIGMS	EIF3 STRUCTURE /FUNCTION IN INITIATION AT IRESS	HERSHEY, JOHN	UNIVERSITY OF CALIFORNIA DAVIS	CA	\$149,290
NIAID	Administrative Core	KRATTIGER, ANATOLE	ARIZONA STATE UNIVERSITY-TEMPE CAMPUS	AZ	\$155,379
NCRR	ROLE OF NONSTRUCTURAL PROTEINS IN PESTIVIRUS ASSEMBLY	GRAKOU, ARASH	EMORY UNIVERSITY	GA	\$35,600
NCRR	NS3 HELICASE	RANEY, KEVIN	BAYLOR COLLEGE OF MEDICINE	TX	\$16,231
NIAID	New Approaches To Active Immunoprophylaxis	PURCELL, ROBERT	NIH		\$836,285
NIDDK	Analysis and Modulation of Virus-Host Interaction in Animal Models	REHERMANN, BARBARA	NIH		\$289,923

Total funding within the \$93 million HCV budget that is being spent on projects not specific to HCV \$4,896,540

Total of four categories - \$23.8 percent of the \$93 million HCV budget \$22,164,370

HCV advocates may protest by joining a petition at HepCop (Hepatitis C Research Oversight Partnership)
<http://www.hcvets.com/NIH/PressRelease/0904.asp>
 It will be distributed to the Office of Government Ethics and to Congressional Appropriations Committees.

Data compiled by:
[FAIR Foundation \(www.fairfoundation.org\)](http://www.fairfoundation.org)
[Massachusetts Hepatitis Patient Empowerment Project \(MaHepPEP at http://www.ma-heppep.org/\)](http://www.ma-heppep.org/)

Data downloaded from:
<http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2008&DCat=Hepatitis%20-%20C>